Remove Antibody Remove Clinical Research Remove Development Remove Immune Response
article thumbnail

Absci and Kennedy Institute partner to expedite immunotherapies development

Pharmaceutical Technology

Absci has collaborated with the University of Oxford’s Kennedy Institute of Rheumatology to expedite the development of AI-driven immunotherapies. The company will then reassemble the antigen-antibody pairs, using its reverse immunology approach, as starting points for the development of drugs.

article thumbnail

China’s NMPA accepts IND for SinoMab BioScience’s SM17 to treat asthma

Pharmaceutical Technology

SM17 is a humanised IgG4-k monoclonal antibody that targets IL-17RB to treat asthma, idiopathic pulmonary fibrosis (IPF), atopic dermatitis (AD) and other immunological disorders. It can suppress Th2 immune responses by binding to IL-17RB on Type 2 innate lymphoid cells (ILC2s).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FairJourney Biologics enters antibody discovery agreement with Pandion Therapeutics using novel discovery platforms

The Pharma Data

FJB) and IONTAS Limited (IONTAS), leaders in the discovery and optimization of VHH and fully human antibodies, today announced they have signed an agreement to discover antibodies with Pandion Therapeutics (Pandion). We now have a pipeline of undisclosed therapeutic partnerships nearing clinical research.

article thumbnail

Gritstone bio trumpets first data for ‘multivariant’ COVID jab

pharmaphorum

A COVID-19 vaccine that could work against multiple variants of the coronavirus – developed by US biotech Gritstone bio – has generated encouraging immune response data in its first clinical trial.

Protein 121
article thumbnail

Eyeing emergency use of COVID-19 drug, Humanigen partners with Lonza to make it

pharmaphorum

Humanigen is hoping for emergency use authorisation in the US for an antibody to treat severe COVID-19 before the end of 2020, and has teamed up with Swiss contract manufacturer Lonza to make sure it can meet demand. Lilly also has studies on the go for LY3127804, an investigational antibody targeting angiopoietin 2 (Ang2).

Drugs 89
article thumbnail

What Innovative Treatments For Metastatic Breast Cancer are being developed?

Find Me Cure

If you follow our blog you know that we at FindMeCure take updating our readership on treatments in development very seriously. This Breast Cancer Awareness Month we’d like to talk about emerging areas in metastatic breast cancer treatment since clinical research has come so far in recent years.

article thumbnail

Oxford’s malaria shot set for phase 3 test after ‘unprecedented’ 77% efficacy

pharmaphorum

Following the success of the coronavirus vaccine developed with AstraZeneca, Oxford University’s Jenner Institute has unveiled trial results showing its experimental malaria shot could be around 77% effective. Vaccine efficacy was 74% and 77% in the low and high dose adjuvant group, respectively.